Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Pill Clear all
Not listed Phase 3 Interventional Accepts healthy volunteers

Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion

NCT04872283
View directory record Official record
Conditions
Ketorolac, Joint Fusion
Interventions
great toe (1st metatarsophalangeal joint) fusion, IV Ketorolac, Ketorolac Pill, 5/325mg Oxycodone-Acetaminophen, Aspirin 81Mg Ec Tab
Procedure · Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Oct 26, 2026, 7:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-intrusive Detection of Temporary Neurologic Impairment by Opioids

NCT05489601
View directory record Official record
Conditions
Neurologic Impairment by Opioids
Interventions
Oxycodone
Drug
Lead sponsor
Zxerex Corporation
Industry
Eligibility
21 Years to 59 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 26, 2026, 7:02 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

NCT00935766
View directory record Official record
Conditions
Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases, Diabetes, Cardiovascular Disease, Glucose Metabolism Disorders, Hypertension
Interventions
Omega-3, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Not applicable Interventional

Post-Operative Pain Control Following Shoulder Surgery

NCT04622839
View directory record Official record
Conditions
Shoulder Pain
Interventions
Tylenol and NSAIDS (Ibuprofen, diclofenac)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Carbidopa for the Treatment of Excessive Blood Pressure Variability

NCT02553265
View directory record Official record
Conditions
Dysautonomia, Familial, Baroreflex Failure Syndrome
Interventions
Carbidopa Low-Dose, Placebo, Carbidopa High-Dose
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
10 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 1 Interventional

Ampicillin for DYT-1 Dystonia Motor Symptoms

NCT01433757
View directory record Official record
Conditions
DYT-1, Dystonia
Interventions
Ampicillin, Sugar pill
Drug
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia

NCT01277107
View directory record Official record
Conditions
Insomnia
Interventions
Zaleplon AP formulation, Placebo capsule
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Pembroke Pines, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Inflammation and Daily Life Study

NCT03771612
View directory record Official record
Conditions
Inflammation
Interventions
Naproxen, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 60 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 26, 2026, 7:02 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions
Gralise
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 26, 2026, 7:02 AM EDT
Active, not recruiting Early Phase 1 Interventional

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction

NCT04676399
View directory record Official record
Conditions
Chronic Pain, Hypertension, Diuretics Drug Reactions, SCS
Interventions
Hydrochlorothiazide 12.5mg, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

NCT02128958
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
CF102, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 26, 2026, 7:02 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 4 Interventional Results available

Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder

NCT00572117
View directory record Official record
Conditions
Bipolar Disorder, Alcoholism, Alcohol Dependence
Interventions
Topiramate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

NCT00117273
View directory record Official record
Conditions
Healthy
Interventions
Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE)
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Inositol in Trichotillomania

NCT01875445
View directory record Official record
Conditions
Trichotillomania, Hair Pulling
Interventions
Inositol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 26, 2026, 7:02 AM EDT
Not listed Phase 2Phase 3 Interventional

An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III

NCT06614894
View directory record Official record
Conditions
Sanfilippo Syndrome, MPS3
Interventions
Ambroxol Hydrochloride 30 mg tablet - 9 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 18 mg/kg/day, Ambroxol Hydrochloride 30 mg tablet - 27 mg/kg/day
Drug
Lead sponsor
Ozlem Goker-Alpan
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

NCT03836001
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
Serlopitant Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal

NCT00661674
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Palonosetron, Hydroxyzine, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2 Interventional Results available

Varenicline for Treatment of E-cigarette Dependence

NCT05541497
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia

NCT01095562
View directory record Official record
Conditions
Cognitive Deficits in Schizophrenia
Interventions
ABT-126, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
20 Years to 55 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Cerritos, California • Costa Mesa, California • Escondido, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 26, 2026, 7:02 AM EDT
Terminated Phase 4 Interventional

Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care

NCT04938388
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Interventions
Semaglutide Pill, Fresh organic vegetables
Drug · Dietary Supplement
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 26, 2026, 7:02 AM EDT
Not listed Phase 2Phase 3 Interventional

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

NCT05637879
View directory record Official record
Conditions
PTSD
Interventions
Glecaprevir/pibrentasvir, Placebo
Drug · Other
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 26, 2026, 7:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Selinexor in Advanced Liposarcoma

NCT02606461
View directory record Official record
Conditions
Dedifferentiated Liposarcoma
Interventions
Selinexor, Placebo
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
12 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 26, 2026, 7:02 AM EDT